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Abstract 
Amiodarone is used in the management of ventricular and atrial arrhythmias, and the drug of 
choice among many cardiothoracic surgeons to manage post-operative arrhythmias. Atrial 
fibrillation with rapid ventricular response, is the most common arrhythmia treated with 
amiodarone in a telemetry unit in one medical center located in northern California. Nurses have 
noted a high incidence rate of phlebitis related to amiodarone infusion even when the current 
hospital guidelines are being followed. Data were collected over six months and included 35 
patients, each infusion via a different intravenous site was considered another occurrence, for a 
total of 40 infusions. There were 16 cases of phlebitis that developed which was a 40% incidence 
rate. Some patients had more than one episode of phlebitis. A multidisciplinary team was formed 
to introduce practice change. Interventions focused on education of staff and implementation of 
evidence-based practice guidelines for infusion. Data collection of phlebitis incidence was 
performed post-intervention over four weeks that included 4 patients with a total of 7 infusions.  
Each infusion was considered as a separate occurrence. There were 3 cases of phlebitis, with one 
patient accounting for two cases. The result is a 43% incidence rate of phlebitis. A follow-up 
study is necessary after six-months of data collection post-intervention in order to make a more 
balanced analysis of the result, and this continuation of data collection is in progress. 
 Keywords: Amiodarone, phlebitis, guideline, side effects, infusion, thrombophlebitis.  
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Amiodarone-Induced Peripheral Phlebitis: Implementation of Practice Guideline to Decrease 
Incidence 
Problem Description 
Managing arrhythmias in a cardiac unit can pose a significant challenge for nurses and 
physicians in their daily practice.  The life-threatening nature of the problem makes it critical to 
have a drug that can be infused readily and can manage the arrhythmias effectively. First 
discovered in 1961, Amiodarone is a Vaughan Williams class III anti-arrhythmic drug 
commonly used in the setting of managing unstable atrial and ventricular arrhythmias (Brady 
Boyce & Homer Yee, 2012). Approved by the Food and Drug Administration (FDA) in 1985, 
the increased use of amiodarone has also been linked to phlebitis. The approval of the FDA is 
limited to the treatment of ventricular fibrillation and ventricular tachycardia. However, the off-
label use of amiodarone in managing atrial arrhythmias, such as atrial fibrillation in the 
postoperative period, has gained popularity among cardiac surgeons, (Hannibal, 2016).  
Endorsed by consensus guidelines published by the American College of Cardiology 
(ACC), the American Heart Association (AHA), and the European Society of Cardiology (ESC) 
in the treatment of atrial fibrillation, the guidelines also acknowledge that one of the common 
side effects when infused peripherally is phlebitis (Spiering, 2014). With its increased use in 
many cardiac-care units, a high incidence of amiodarone-related phlebitis has also been noted, 
prompting three major nursing journals in the last few years to address this issue (Hannibal, 
2016).  With an increasing number of patients presenting for hospital admission with atrial 
fibrillation, or having atrial fibrillation post-cardiac surgery, combined with the drive to manage 
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atrial arrhythmias to avoid complications such as stroke, the likelihood that healthcare 
institutions will continue to use amiodarone to manage such diagnoses is high. 
Phlebitis is defined as an inflammation of the vein wall characterized by pain, edema, 
erythema, streak formation and/or a palpable cord (Washington & Barrett, 2012). The Infusion 
Nurses Society (INS) phlebitis scale is widely used in the clinical setting to grade the severity of 
phlebitis, in a range from 0 to 4, with 4 being the most severe. An additional phlebitis scale; the 
visual phlebitis scale is another alternative assessment tool widely used in grading the severity of 
phlebitis (see appendix A for both phlebitis scales). According to INS (2011), the rate of 
phlebitis should be 5% or less in any given population of patients receiving peripheral infusions. 
The 2016 INS Intravenous Therapy Standards of Practice identified four categories of phlebitis: 
chemical, mechanical, bacterial, and phlebitis driven by patient characteristics. The INS also 
acknowledged post-infusion phlebitis that can develop due to any of the same causes. 
Amiodarone-related phlebitis, in particular, can be categorized under chemical phlebitis. The 
chemical features of amiodarone, such as its acidity, have been thought to be a major culprit in 
phlebitis formation with amiodarone infusion (Spiering, 2014). 
 
It has been noted that there is a direct connection between pH and osmolarity of an 
infusate contributing to phlebitis formation. In the case of amiodarone, it is hypothesized that the 
acidic pH level (ranging from 3.4-4.5 in some literature) is more responsible for phlebitis rather 
than the osmolarity (Spiering, 2014).  Pharmaceutical companies are well aware of the 
complication of phlebitis when amiodarone is infused peripherally. Information on how to avoid 
phlebitis is included in the prescribing information from the various manufacturers, and has 
included recommendations for using an in-line filter to reduce particulate formation, use of 
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central venous catheter for infusions longer than one hour, and if the drug concentration is 2 
milligram(mg)/ milliliter (ml) and higher (Baxter Healthcare Corporation, 2018).  Ideally, it is 
recommended that all infusions should be given via central venous catheter due to phlebitis as a 
known side effect. However, this is not always feasible since intravenous amiodarone is usually 
prescribed during emergencies or when patients develop arrhythmias where timing is not always 
predictable. In many cases, a central line is not always readily available for all patients. 
 
In addition to pH and osmolarity contributing to phlebitis, the preservatives added to 
amiodarone and the drug’s inherent tendency to precipitate when it enters the blood stream have 
also been hypothesized as causative factors. The conventional amiodarone preparation contains 
preservatives such as polysorbate 80 and benzyl alcohol, both thought to contribute to phlebitis 
formation. Some pharmaceutical companies have done their best to eliminate such preservatives 
in their packaging. With regard to precipitation of amiodarone once diluted or in contact with the 
bloodstream, a study by Ward and Yalkowsky (1993) using animal subjects found that rapidly 
forming needle-shaped crystals adhere to the intima of the vein causing trauma to the vascular 
endothelium when amiodarone is infused. Smaller volume infusions did not illicit the same 
inflammatory response, but as the volume of amiodarone infused increased, so did the severity of 
thrombophlebitis. It is then hypothesized that even when the amiodarone infusion was diluted, 
the amount of precipitation still exceeded the solubility of the drug in the bloodstream (Mowry & 
Hartman, 2011). 
 
Phlebitis has been well-known as a side effect of amiodarone infusion for many years and 
thus, hospitals across the country have conducted studies to improve practice and minimize it. In 
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2014, Spiering, a cardiology clinical nurse specialist at Providence Saint Vincent Medical Center 
in Oregon at the time, conducted a study and published the results in the Journal of Infusion 
Nursing. The study found that the implementation of amiodarone peripheral infusion guidelines 
significantly decreased the incidence rate of phlebitis from 85% pre-guidelines down to 38% 
post-guidelines, representing a 47% improvement. It also showed reduced severity of phlebitis 
after the guidelines were implemented. The study was conducted in response to nurses reporting 
a high incidence of phlebitis in a telemetry unit, causing pain and infection in patients, and often 
delaying discharge. There were no existing guidelines for amiodarone infusion at the facility 
before the study. Study patients were identified from those admitted to a single institution, using 
an observational convenience sample consisting of 34 patients over a six-month period.  A multi-
disciplinary team was formed including nurses, cardiologists, pharmacists, and the intravenous 
(IV) therapy team, and an approval from the Institutional Review Board (IRB) was obtained. 
Multiple peer-reviewed research articles were used in the development of the guidelines.  
The effective guidelines included use of dedicated lines, separate filters for boluses and 
infusions, patient instruction to notify a nurse immediately in case of pain or redness at the site, 
inspection of the IV site during change of shift report, and discontinuation of catheter at the first 
sign of pain and redness.  Although the guidelines appear to be successful in decreasing the 
incidence of amiodarone-related phlebitis, the sample size was small and the population used 
were strictly adult cardiac patients. Therefore, the study may not be generalizable to the rest of 
the hospital population. There is also a question of whether or not the decrease in phlebitis can be 
attributed to the guideline themselves, or was merely a response to an increased awareness and 
understanding of amiodarone complications on the part of staff.  
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In a study published in Critical Care Journal, Brady Boyce & Homer Yee (2012) 
conducted a study to determine the rate and severity of phlebitis related to peripheral infusion of 
amiodarone and to evaluate the magnitude of the problem at Mount Auburn Hospital in 
Massachusetts. Nurses were reporting a high incidence of phlebitis even when existing 
guidelines for drug administration was being followed. Those guidelines included having 
amiodarone prepared in a glass bottle from pharmacy, and the use of an in-line filter in case of 
drug precipitation. The study included a review of the current literature and of the hospital’s 
current policy and procedures. The hospital’s IRB was consulted, and a multidisciplinary team 
was formed including nurses, an IV therapy nurse, a cardiovascular nurse specialist, a 
pharmacist, and a research advisor.  
Using a descriptive design, data was collected over a six-month period using a 
convenience sampling of 12 patients.  Each infusion of amiodarone was treated as a separate 
occurrence, for a total of 24 infusions. A collection tool drafted by the multi-disciplinary team 
was used to aid in determining variables that would affect phlebitis development. This tool was 
then submitted and reviewed by the nursing research council prior to its use and face validation 
was established. The study was stopped after six months due a high rate of phlebitis, and a plan 
for action to prevent further harm to patients was initiated immediately. The study showed 
various grades of phlebitis developed in eight patients (67%), and phlebitis developed at 12 of 
the 24 infusion sites (50%). This was a far higher rate than that reported in the literature, which is 
between 7-23% (Brady Boyce & Homer Yee, 2012). The high rate of phlebitis warranted a plan 
to increase awareness and education for nurses and other medical staff, as well as a change in the 
policy and practice guidelines and subsequent implementation of those changes.  
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These changes to practice included involvement of the IV therapy nurse to monitor 
infusion sites, annual competency testing for nurses regarding amiodarone infusion, increasing 
the frequency of IV site assessment, use of in-line filters during infusion, and reminding 
physicians about the risk of phlebitis associated with amiodarone infusion to alert them to 
carefully consider the length of infusion and possible conversion to oral route of administration. 
The small sample size was identified as one of the limitations of the study, although it was 
enough to make changes to policy and practice guidelines promptly. The result, even from a 
small sample, combined with the known common side effect of amiodarone, triggered the 
appropriate response by the medical center to consider patient safety as their top priority. There 
is, however, no outcome study or follow up data mentioned in the study to determine whether the 
changes made decreased the incidence of phlebitis at this facility. 
Another study published in American Journal of Critical Care by Norton, et al. (2013) at 
Stanford University in California, examined the magnitude of the problem of amiodarone-related 
phlebitis in a critical care unit (CCU). Staff recognized the problems of amiodarone-related 
phlebitis when infused peripherally even when the current recommendations of drug 
administration were being followed. The current protocol of the facility at the time of the study 
called for use of an in-line filter, central line for higher concentration of the drug, and only used 
peripheral lines for lower drug concentrations. The guidelines were insufficient as evidenced by 
the high incidence of phlebitis and the need for refinement was recognized.  
A retrospective descriptive study over an 18-month period was conducted with a total 
sample of 105 patients. The study found the incidence of phlebitis to be 40% with a 50% 
recurrence rate.  All cases of phlebitis occurred in patients who received a total dose of 3 grams 
peripherally, and one quarter of the cases developed phlebitis at dosages less than 1 gram per 
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dose, with complications occurring within 24 hours of treatment (Norton, et al., 2013). Results of 
the study clearly warranted a change in practice policy which included continuing use of an in-
line filter, using the largest peripheral vein for infusion, converting to oral dosing within 24 
hours of IV administration, insertion of percutaneous central catheter if infusion exceeded 24 
hours, creation of pharmacy order set, and mandatory assessment of the IV site by nurses. The 
study emphasized that an outcome study would be needed to measure the effectiveness of the 
changes adopted in their practice policy.   
 
Rationale 
 Intravenous amiodarone is widely used in the management of rapid control of arrhythmias in the 
author’s microsystem, a telemetry unit located in northern California. The high utilization of 
intravenous amiodarone in the management of arrhythmias has brought attention to an 
accompanying high rate of phlebitis related to the infusion. The author tracked and collected data in 
collaboration with charge nurses in her unit and has shown a 40% incidence rate over a six-month 
period in 35 patients with repeat occurrence of phlebitis in some. A total of 40 infusions resulted in 
16 case of phlebitis. The high incidence rate of phlebitis has caused pain and discomfort to patients, 
extending hospital length of stay (LOS), thereby, increasing cost, and contributes to lower score on 
patient satisfaction survey. According to HealthCare.gov (2018), the average cost of a three-day 
hospital stay is around $30,000. Prolonged length of hospital stay due to phlebitis complication can 
significantly contribute to high cost in healthcare expenditure. In severe cases, sepsis can develop, 
further extending length of hospital stay and causes suffering of patient. 
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Currently, the only practice guidelines at the author’s microsystem are the use of a 0.22 
micron in-line filter when administering amiodarone, and the mandatory use of central lines for 
infusions of concentrations exceeding 2 mg/ml. In addition, there is no available policy and 
procedure related to amiodarone infusion with regard to management of intravenous 
complications, such as phlebitis and medication extravasation. The hospital currently uses pre-
mixed amiodarone intravenous bags from the hospital’s chosen pharmaceutical supplier with a 
concentration of 0.5 mg/mL for intravenous bolus, and 1.8mg/ml for continuous infusion. The 
ongoing high incidence of amiodarone-related phlebitis at a northern California medical center, 
telemetry unit, warrants attention to address such complication. Using the graphic cause and 
effect diagram, also known as an “Ishikawa diagram,” the author laid out the possible reasons for 
the high incidence of amiodarone-related phlebitis in her microsystem (see appendix B for the 
Ishikawa diagram). 
 
With the increasing demands for evidence-based approaches on healthcare practice, it is 
important for clinicians to base their decisions on the best available scientific evidence. A key 
step in finding answers based on evidence-based practice is framing the clinical question in an 
organized manner to find the answer. PICOT is a strategy and is widely used in framing clinical 
and research questions, and aids in formulating questions clearly and concisely. First introduced 
in 1995 only as PICO, it was eventually expanded by adding the letter “T,” hence, eventually 
became known as PICOT (Davies, 2011).  The acronym stands for the following: P - patient or 
problem, I - intervention, C - comparison, O - outcome, and T - for time. By utilizing this 
framework, the author formulated a clinical practice question aimed at improving clinical 
practice and patient care in a cardiac microsystem. The formulated question the author designed 
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using the PICOT framework for her planned practice improvement is: “In cardiac patients 
developing peripheral phlebitis during amiodarone infusion, how does the implementation of 
expanded evidence-based-practice (EBP) guideline compared to the current hospital infusion 
guidelines will affect the incidence rate of phlebitis over a period of four weeks?”  Through 
interventions such as educational program and implementation of EBP guideline related to 
amiodarone infusion, the author’s expectation is that the incidence rate of phlebitis will decrease 
and lead to better patient outcomes. 
Specific Aim 
By introducing evidence based-change of practice guideline to improve patient care 
delivery, the goal is, by August 2018, the implementation of expanded amiodarone infusion 
guidelines in a telemetry unit will result in a 20% decrease in the incidence of peripheral 
phlebitis related to amiodarone infusion. 
 
Context 
 The author’s microsystem is a cardiac-driven unit, with a 30-bed capacity, located in 
Northern California.  It is a multi-specialty unit with the primary focus in caring for patients 
needing services ranging from coronary/cardiac interventions, cardiothoracic surgeries, cardiac 
device implants, care post myocardial infarction, and care of various cardiac-related symptoms. 
The average length of stay of four to five days. Patient-to-nurse ratio is usually 4:1, but changes 
to 3:1 when the patient assignment involves recovering patients with post coronary artery 
interventions, trans-catheter aortic valve replacements (TAVR), and cardiac ablations (see 
Appendix C for microsystem profile). The make-up of employees and patients reflect the city’s 
wide demographics of varying cultural backgrounds. Patients and staff are culturally and 
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ethnically diverse. The diverse composition of staff is beneficial in delivering culturally-sensitive 
care for most patients. 
 With the primary medical care focus on cardiac-related diagnoses, amiodarone infusion is 
a common occurrence in this microsystem. Current hospital infusion guidelines regarding 
amiodarone infusion consist of the use of in-line filter, and central line requirement for drug 
concentration of 2mg/ml. These guidelines are actively being followed by staff, however, the 
incidence rate of phlebitis remains noticeably high, prompting the author to conclude that the 
current guideline is insufficient to prevent the occurrence of amiodarone-related phlebitis. 
Further intervention is needed to alleviate such a problem. 
 
Intervention and Methods 
 Quality improvement (QI) methods have been a common trend in healthcare to support 
the delivery of quality care that is also timely, safe, and effective, as well as cost efficient. Of the 
many QI tools and methods, the Plan-Do-Study-Act (PDSA) cycle is the method for quality 
improvement the author has chosen to use for the planned change of practice. The PDSA cycle, 
first introduced to Dr. Deming by his mentor, Walter Shewhart of the famous Bell Laboratories 
in New York, is a systematic process for acquiring valuable learning and knowledge for the 
continual improvement of a product, process, or service (The W. Edwards Deming Institute, 
2018). 
 PDSA method offers the benefit of learning as quickly as possible whether an 
intervention works and thus allowing the system to make adjustments accordingly to achieve the 
desired improvement (Reed & Card, 2016). Unlike controlled trials, PDSA allows the flexibility 
of new learning to be built in to the experimental process where, if problems are identified with 
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the original plan, then the theory is easily revisable to fit the new learning and one can then 
proceed to test its effectiveness in achieving the planned change.  Using this method allows 
continual identification of further problems that might need to be addressed. The adaptability of 
PDSA is an important feature that is valuable in this current complex state of healthcare systems 
where change has become constant (see appendix D for the PDSA cycle for the improvement 
project). 
 The planning stage started with assessment and recognition of the problem in the 
microsystem. The author discussed the evident problem with the manager/preceptor and the 
planned evidence based-change of practice project plan. The author recruited team members with 
varying key roles that consisted of three charge nurses from different shifts, an intravenous 
nurse, and a pharmacist. Charge nurses are tasked with assisting the author in disseminating 
information to staff on their respective shifts about the planned change in practice. The charge 
nurses were assigned to assist in gathering and recording amiodarone infusions and any phlebitis 
incidences in a designated log book. The author set up an informational interview with the 
intravenous (IV) nurse to discuss intravenous lines, vein anatomic variations and other subjects 
related to intravenous therapy. The pharmacist was tasked to serve as an expert for information 
regarding amiodarone infusion, facility infusion guidelines, and pharmaceutical-related 
prescribing information. The author was responsible for literature searches and designing a 
knowledge assessment of staff related to educational program. A Gantt chart was constructed to 
provide a detailed timeline of the change in practice project (see appendix E). Together with the 
team assembled, the author and team members proceeded to the next phase of PDSA cycle; the 
“Do” phase.  
 Acting on the planned practice change required constant discussions with team members. 
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Charge nurses reminded staff during huddles about the improvement projects, and also recorded 
demographic information about patients and their amiodarone infusion dates, sites, and gauge 
sizes of intravenous catheter used. Most importantly, when patient developed phlebitis, grading 
of phlebitis was recorded using the INS phlebitis scale in the log book.  The IV nurse 
recommended further exploration of INS practice regarding phlebitis management. She assisted 
in discussing causes of phlebitis, treatment, and the most current best practice recommendations. 
She also discussed ideal locations for intravenous sites, and gauge size of catheter ideal for 
infusing acidic substances, such as amiodarone. Her recommendations were consistent and 
validated by INS during the author’s literature search.  
 The Pharmacist provided amiodarone infusion guideline recommendations based on the 
pharmaceutical prescribing information, and discussed the current packaging and the 
pharmaceutical company used by the hospital as the supplier. The information aided the author 
in structuring the literature search and helped narrow the focus to that particular supplier.  In 
addition, current hospital infusion guidelines were also discussed by the pharmacist with the 
author. The author performed literature searches regarding amiodarone infusion, phlebitis, and 
extended the search to include amiodarone extravasation. Literature review was performed using 
CINAHL, Cochrane, Google Scholar, PubMEd, and 1Findr. The author accessed and reviewed 
various guidelines, policy and procedures at her institution related to infusion causing phlebitis 
or extravasation.  The author was able to establish communication via e-mail with one author, 
discussing her published amiodarone infusion guideline (see appendix F) and requested 
permission to adapt her published infusion guideline for educational purposes, to which she 
graciously agreed. (M. Spiering, personal communication, June 14, 2018).  
  To accurately gasp the level of knowledge staff have regarding amiodarone infusion, the 
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author distributed a baseline amiodarone nursing knowledge assessment (see appendix G for the 
knowledge assessment questionnaire). The author then assembled all the information and 
prepared an educational poster used to educate staff about amiodarone infusion and phlebitis. 
Backed by literature search and EBP, the poster was then used to educate staff and displayed in 
the nursing unit for staff viewing and reference. Education was provided to all nursing staff 
across three different shifts discussing amiodarone and phlebitis, emphasizing the EBP infusion 
guideline implementation shown in the poster, and providing answers and feedback to staff over 
the course of several weeks.  In addition, the author simultaneously had ongoing discussions with 
team members on how to best record and maintain the amiodarone log book in a format that was 
easy to access and record information.  This format was modified recording according to 
feedback from team members and other staff.  In addition, the author provided staff assistance in 
evaluation of phlebitis incidences on some patients, and seized the opportunity to include 
patients in educating them about amiodarone infusion by encouraging their participation in the 
prevention of amiodarone-related phlebitis complications.  Patients were instructed to notify staff 
immediately for any early signs and symptoms of phlebitis, such as pain and redness to infusion 
site. 
Study of the Intervention 
 In order to identify whether or not interventions are effective for any process 
improvement project, it is important to study the efficacy and potential generalizability of these 
interventions for improving practice in healthcare.  Continually utilizing the PDSA method for 
change of practice project, the letter “S,” which stands for “study”, is appropriately assigned and 
can be utilized as a guide for what is next in a sequence of steps in evaluating practice 
improvement interventions that were enacted. To study the reliability and effectiveness of 
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interventions, the author first measured the baseline nursing knowledge of nursing staff related to 
amiodarone infusion before the educational program and guidelines were implemented. The 
author then re-measured their knowledge after four weeks of the educational program by using 
the same survey questions that were initially distributed at the baseline knowledge assessment.  
This measure provides an opportunity to evaluate differences in knowledge acquisition, and 
whether or not this will translate to change in nursing practice, which could lead to eventual 
decrease in incidence rate of amiodarone-related phlebitis in the microsystem.  
 Another method in addition to studying and evaluating interventions was to compare the 
number of cases of amiodarone-related phlebitis before and after the educational program and 
guideline implementation. By comparing the incidence rates, any changes in the phlebitis rate 
could be attributed to the interventions that were initiated. however, it can be difficult to 
determine whether an improvement in incidence rate is related to guideline implementation, or 
due to increased understanding and awareness of the amiodarone side effects on the part of staff; 
or both. The result revealed an increased in incidence rate post-interventions. However, it is 
important to consider the imbalance in the length of time data collection that was performed. The 
discrepancy is due to limitation in time allotted for this improvement project, which only allowed 
four weeks to collect data post educational program and guideline implementation due to the 
academic deadline set by the educational institution. The author however, has extended the data 
collection to go over a six-month period to match the data collection time pre-and post-
intervention.  
 The last stage of PDSA cycle, “Act,” required the team to constantly reflect and analyze 
the interventions and the results being collected, adjusting the protocols as they saw fit in order 
to improve the process. With the tracking of amiodarone-related phlebitis, for example, the log 
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book was continuously updated to make it user-friendly for staff to log amiodarone infusions and 
phlebitis formation over the course of four weeks. The team provided support and feedback, as 
well as reinforced staff education, since initial results post-intervention have remained above 
goal. They have also reexamined the process further to identify any opportunities for 
improvement. Adjustments have been made to adapt in differences in staff’s learning needs and 
style. Ongoing plans to re-evaluate the effectiveness of adjustments are in works. The PDSA 
cycle is an ongoing process, making changes as needed to improve the process, with the goal of 
staff’s adaptation to process improvements in order to eventually become more efficient as these 
improvements slowly become embedded to the microsystem. The success of the planned change 
relies on staff compliance once it is implemented. Results of the interventions are discussed 
further in the following sections of this manuscript.  
Measures 
 To determine whether or not there were any changes to nursing knowledge regarding 
amiodarone and phlebitis, a survey of 56 nursing staff from three different shifts was conducted, 
assessing their knowledge regarding amiodarone infusion and phlebitis before and after the 
educational program. The questionnaire was designed by the author based on her observations of 
the knowledge needed in her microsystem, and what was used in literature in addressing staff’s 
knowledge deficit related to amiodarone infusion. The author designed the survey questions 
factoring in the current limited hospital guideline in place. The same survey questions were 
administered to nursing staff again after the educational program to determine any changes in the 
knowledge level of staff regarding amiodarone infusion and phlebitis. Results were then gathered 
and broken down into the specific questions that were used in the survey. Baseline nursing staff 
knowledge assessment results (see appendix H) were presented in graphical format for ease in 
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interpretation. Post-educational program nursing staff knowledge assessment results were also 
presented graphically (see appendix I) for consistency in data presentation. The author also 
compared the incidence rate of amiodarone related phlebitis before and after the educational 
program and with the implementation of infusion guideline. This is to determine whether 
knowledge level of staff and implementation of an infusion guideline are factors in any changes 
to the incidence rate of phlebitis. 
 There are no available metrics specific to amiodarone-related phlebitis in the 
microsystem.  However, the development of phlebitis can affect patient satisfaction, length of 
stay due to complication, and cost containment; all considered metrics that matter in any 
healthcare industry, including in this microsystem. Benchmarking was performed with other 
medical and academic institutions using published literature and studies of the incidence rates, 
improvement processes, and outcomes. There is no current national benchmark specific to 
amiodarone-related phlebitis, however, INS (2011) has indicated that phlebitis rate in any given 
population should only be 5% or less when receiving peripheral infusion. 
 To identify any improvements, the team collected data after educational program and 
guideline implementation, tracking all amiodarone infusions in the microsystem. Data collection 
included the following information: patient demographics, medical record number, diagnosis, 
amiodarone infusion timeframes, IV sites information, and phlebitis scale utilization. Data 
regarding amiodarone infusion and phlebitis incidence rate post-educational program and 
guideline implementation were gathered over the course of four weeks. Results were then 
compared to data of amiodarone infusion and phlebitis rate incidence collected before 
educational program and infusion guideline implementation. 
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Analysis/Discussion 
 Quantitative and qualitative methods were used in the improvement project to obtain the 
data necessary to draw conclusions. The survey questions for assessing both baseline and post- 
educational program nursing knowledge were designed as qualitative measures, but, in order to 
analyze the answers more easily, a numerical value was assigned and made the analysis 
quantifiable. The graphical representation and display of the results were another method of 
presenting the data quantitatively. In addition, a multiple-choice question was utilized to select 
an answer that best described the nursing staffs’ preference involving infusion site and IV gauge. 
The data collected regarding the rate of phlebitis incidence prior to educational program and 
guideline implementation were collected over a period of six months. This data showed a 40% 
rate of amiodarone related phlebitis. On the other hand, the data collected post-educational 
program and guideline implementation was only over a period of 4 weeks, and showed a 43% 
incidence rate of phlebitis. The result revealed a higher incidence, opposite of the goal of lower 
incidence. It is however too early and premature to drew a final conclusion of the interventions’ 
effectiveness, since the data collection was done on a very short time after the interventions were 
initiated, and sample population is still small. An outcomes study is in progress and an analysis 
of the true effectiveness of the study is pending. 
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Results 
The educational program for nursing staff and implementation of EBP infusion guideline 
related to amiodarone resulted in increased understanding of nursing staff. However, the 
incidence rate of phlebitis remained high and above goal, and is not reflected in the early results 
of the study. The incidence rate pre-interventions were collected over a six-month period, 
showing a 40% versus over four-weeks post-interventions showing a 43% phlebitis incidence 
rate. It is however, important to note that the initial result is not a true indication of the 
effectiveness of the interventions, due to time limitation in data collection post-intervention and 
sample size of the population. The author has extended the data collection to go over a six-month 
period. The ability to draw a balanced comparison and to arrive at a final conclusion are not 
possible at this time. An outcomes evaluation will be made six months after the interventions 
were enacted to truly assess the effectiveness of the quality improvement project.  
Summary 
 A key to resolving the high incidence of amiodarone-related phlebitis is the utilization of 
EBP standards and addressing knowledge deficits of staff. By increasing knowledge and utilizing 
EBP guideline, the goal was to promote early detection, apply knowledge learned, and encourage 
vigilance in monitoring IV sites during infusion. The author is confident that the educational 
program and the implementation of amiodarone infusion best practice remains the key to 
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resolving high incidence of phlebitis in her microsystem. Although the initial result has not 
shown any impact in lowering the incidence, the author believes that eventually, the 
interventions will be successful, and will be reflected in the final outcomes study that is currently 
pending. By slowly introducing staff and immersing them to EBP approaches, improvement 
project can be successful and can only lead to a better health outcome. 
Interpretation 
 After implementation of quality improvement interventions, initially, the incidence rate 
of phlebitis remained high. Similar studies reported that an improvement in phlebitis rate when 
implementation of infusion guidelines and staff education were adopted. Others have made 
successful similar efforts after recognizing the problem, while others have adopted changes in 
their practice protocol with outcome study pending at the time of publication.  Knowledge of 
staff regarding amiodarone infusion in the microsystem improved, as was reflected in their post 
educational survey results. However, improved knowledge did not equate to a lower phlebitis 
rate, at of this writing.  On the other hand, the final outcome cannot be analyzed fully until six 
months of data has been collected to see whether the interventions were truly effective. The 
engagement and the sustainability of staff compliance with the infusion guideline will also be a 
factor that will be determined over time. If successful, replication of the improvement project 
processes can be instituted at other cardiac-focused units.   
Limitations 
 Initial results in this quality improvement project are not comparable to pre-intervention 
data due to the unequal time in data collection after implementation of intervention. The sample 
size is small and the length of time for data collection is very short. An effort to extend the data 
collection over six-month period is in progress to determine the real impact of the intervention 
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and evaluate the outcome of study. Another possible limitation to the study is distinguishing 
whether any improvement in the trend of phlebitis incidence in the future is a direct result of the 
infusion guideline implementation, or a result of increase awareness of staff about the side- 
effects of amiodarone infusion. However, it is also possible that it could be related to both 
reasons. The result of the project is limited and not generalizable beyond the adult cardiac 
population. 
Conclusion 
 Managing amiodarone-related phlebitis poses a challenge in a cardiac-focused 
microsystem. The frequency of using amiodarone to manage arrhythmias continues, and the need 
to control the high incidence of amiodarone-related phlebitis remains pervasive. Attempts to 
alleviate such issues have been addressed, and the nursing profession is instrumental in 
attempting to find solutions to decrease the incidence, as evidence by the availability of multiple 
published nursing-led research addressing the issue.  Nurses are in key positions to detect, 
educate, and intervene when there is an obvious breakdown in care management affecting the 
delivery of quality care. The nursing profession has evolved over time, and nursing research 
focusing on the delivery of quality care based on evidence based-practice is the trend specific to 
nursing in healthcare.  
 In response to quality care issues, a role was created in the nursing profession; the clinical 
nurse leader (CNL). The nursing role most suited for improvement project is that of a CNL. A 
CNL may serve as a point-of-care clinician, outcomes manager, risk anticipator, and as an 
educator just to name a few of the roles.  An evidenced based change-in-practice project such as 
decreasing the incidence of peripheral phlebitis related to amiodarone infusion, is the type of 
improvement project for which the CNL role was created. The nursing implications for an 
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evidence-based project like this is that it can be replicated by any telemetry nursing unit looking 
to improve patient outcomes related to amiodarone infusion, and can ultimately contribute to 
improved quality of care, greater patient satisfaction, and decreased healthcare costs.  
 As nurses are on the frontline in healthcare delivery, it can be argued that they make the 
biggest impact in patient care. Improvement projects such as addressing phlebitis incidence in 
collaboration with a CNL and other multi-disciplinary team is providing quality nursing care. 
The current healthcare climate is driven by quality measures and since payments are increasingly 
tied to performance, providing quality care has become the focus of every healthcare 
organization. Quality care and EBP have now become synonymous, and therefore, the utilization 
of CNL skills will likely expand in the future. The roles specific for CNL are aligned with the 
goals and direction of the healthcare industry in general. 
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Appendix A 
 
Types of Phlebitis 
 
 
 
 
 
 
 
 
 
  
Figure A1.  Adapted from Infusion Nurses Society. (2016) Infusion therapy standards of practice. 
Journal of Infusion Nursing, 39, (1S), 95-10. Copyright 2016 by Infusion Nurses Society. 
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Appendix B 
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Figure B1. Ishikawa Diagram: Factors contributing to the development of high 
incidence of amiodarone-related peripheral phlebitis in a cardiac-focused. . 
microsystem 
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Appendix C 
The Cardiac Microsystem Profile 
Note. Inpatient Unit Profile. Adapted from The Dartmouth Institute. (2018). Clinical 
microsystems. Retrieved from http://clinicalmicrosystem.org/knowledge-center/workbooks. 
AMIODARONE-INDUCED PHLEBITIS 30 
 
Appendix D 
 
The PDSA Cycle 
 
 
 
 
 
 
 
  
Figure D1. Quality improvement method used for a change-in practice project related to 
amiodarone infusion causing high incidence of phlebitis in a cardiac-driven unit.  
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Gantt Chart 
 
 
 
Figure E1. Change in practice project timeline to decrease the incidence of peripheral 
amiodarone-related phlebitis in a cardiac-driven unit.  
GANTT	CHART:	CHANGE	IN	PRACTICE	PROJECT	TO	DECREASE	INCIDENCE	OF	PERIPHERAL	AMIODARONE	PHLEBITIS
Week	1 Week	2 Week	3 Week	4 Week	5 Week	6 Week	7 Week	8 Week	9 Week	10 Week	11 Week	12
PLANNING
Microsystem	Reassessment,	Discussed	
planned	project	with	preceptor,	day	shift	
staff.	Team	building:	met	with	charge	
nurses	all	3	shifts,	IV	nurse,	and	
pharmacist.	Reviewed	guideline	and	
policy.
Literature	review,	revised	SOD,	discussed	
project	with	day/	pm/noc	shift	staff.	
Baseline	survey	of	staff’s	knowledge	of	
amiodarone.
Literature	review,	e-mailed	3	published	
authors	related	to	amiodarone	phlebitis.	
Updated	preceptor,	team	building,	met	
with	PICC	line	/IV	nurse.	Collection	of	
baseline	knowledge	continues.	Create	a	
log	book	for	tracking	infusion/	phlebitis.	
Review		expanded	EBP	guideline	with	
team.
	IMPLEMENTATION:
Provide	education	to	staff	every	shift.	
Provide	feedback.	Discuss	timeline	for	
project.	New	guideline	implementation.	
Start	tracking	infusion/phlebitis.	Ongoing	
discussion	with	team	members	and	
preceptor.	Monitor	log	book	and	
implementation.	Involve	patient	with	
education.
	EVALUATION/DATA	ANALYSIS:
Meet	with	team	members.	Reassessed	
knowledge	of	staff.	Distribute	the	same	
survey	questions	collected	for	baseline	
knowledge.	Compare	current	knowledge	
to	baseline	data.	Compare	incidence	rate	
of	phlebitis	pre	and	post	guideline	
implementation.	Discuss	trends	with	
team	member,	staff	and	preceptor.
Write	Final	N653	Paper
Prepare	Poster	Presentation
Present	Poster	at	USF
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Appendix F 
 
Guideline for Peripheral Amiodarone Infusion 
 
1. USE DEDICATED LINE 
a. No other medication is injected or infusing with amiodarone 
b. Always have two lines.  One for amiodarone and one for other medications the 
patient may need 
2. ASSESS THE IV PRIOR TO INFUSION 
a. Assess for pain, redness, and assure an adequate flush with 10ml of NS 
b. If any issues, document infiltration and phlebitis scale 
c. Use the smallest catheter possible in the largest vein 
d. Never use an area of joint flexion 
e. Use a catheter stabilization device, such as Statlock 
3. USE A SEPARATE FILTER FOR AMIODARONE BOLUS AND INFUSION 
4. CHECK THE SITE AFTER BOLUS, AND REMOVE THE IV FOR PAIN 
5. INSTRUCT PATIENT TO IMMEDIATELY NOTIFY RN FOR ANY PAIN, 
REDNESS, OR OTHER CHANGES 
a. Remove the IV at FIRST sign of pain (does NOT have to be red to begin vein 
irritation) 
b. Continue the infusion through a different IV catheter 
6. INCLUDE THE IV SITE INSPECTION (not just the drip) DURING CHANGE OF 
SHIFT REPORT 
7. AT FIRST SIGN OF PAIN, REDNESS, INFILTRATION OR PHLEBITIS, ASPIRATE 
AS MUCH MEDICATION FROM THE CATHETER AS POSSIBLE, THEN 
DISCONTINUE IV 
a. Clean area with CHG 
b. Apply ice pack 
c. Elevate the affected arm.  
d. Document using Infusion Nurses Society approved phlebitis scale 
 
Note. Adapted with permission from Mary Spiering MN, RN, CNS, Professional Practice Program 
Manager. Magnet Program Director Nursing Administration, Kaiser Westside Medical Center, 
Hillsboro, Oregon. The study was completed at Providence Saint Vincent Medical Center, where 
she was previously employed. 
 
 
 
 
 
 
Appendix G 
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Survey Questions Used in Assessment of Nursing Staff knowledge 
 
 
 
Appendix H 
NURSING	STAFF	KNOWLEDGE	ASSESSMENT	RELATED	TO	AMIODARONE	INFUSION:	
	
SCALE:	
1=	Poor	
2=	Below	Average	
3=	Average	
4=	Above	Average	
5=	Outstanding	
	
	
Please	rate	your	knowledge	on	a	scale	of	1	to	5	as	above:			
	
A.	
	
1. What	is	your	knowledge	regarding	the	drug	Amiodarone?	
	
2. How	familiar	are	you	with	the	possible	side	effects	of	peripheral	amiodarone	infusion?	
	
3. What	is	your	knowledge	of	the	rate,	dosing,	and	set	up	of	intravenous	amiodarone	
infusion?	
	
4. Your	knowledge	of	Infusion	Nurses	Society	phlebitis	scale?	
	
5. Your	knowledge	of	different	causes/	types	of	phlebitis?	
	
6. What	is	your	knowledge	on	how	to	treat	phlebitis?	
	
7. What	is	your	understanding	of	the	length	of	time	it	takes	for	phlebitis	to	appear?	
	
	
B.	WHICH	IV	SITE	DO	YOU	PREFER	TO	INFUSE	THE	AMIODARONE	DRIP?	(circle	one	answer)	
a. 	18	gauge,	large	vein	
b. 	18	gauge,	small	vein	
c. 	22	gauge,	small	vein	
d. 	22	gauge,	large	vein
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Results of Baseline Nursing Staff Knowledge Assessment Related to Amiodarone Infusion 
(Before Educational Program) 
 
 
Figure H1. Breakdown results of nursing staff baseline knowledge assessment related to 
amiodarone infusion based on the designated question. Scale rating of knowledge equivalent are: 
1=poor, 2=below average, 3=average, 4=above average, 5=outstanding. 
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1.  What is your knowledge regarding the drug amiodarone?
1
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3
4
5
COMBINED RESULTS OF ALL 3 SHIFTS RESPONDENTS
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Results of Baseline Nursing Staff Knowledge Assessment Related to Amiodarone Infusion 
(Before Educational Program) 
 
 
 
Figure H2. Breakdown results of nursing staff baseline knowledge assessment related to 
amiodarone infusion based on the designated question. Scale rating of knowledge equivalent are: 
1=poor, 2=below average, 3=average, 4=above average, 5=outstanding. 
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32%
48%
18%
2. How familiar are you with the possible side effects of peripheral 
amiodarone infusion?
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5
COMBINED RESULTS OF ALL 3 SHIFTS RESPONDENTS
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Appendix H 
 
Results of Baseline Nursing Staff Knowledge Assessment Related to Amiodarone Infusion 
(Before Educational Program) 
 
 
 
Figure H3. Breakdown results of nursing staff baseline knowledge assessment related to 
amiodarone infusion based on the designated question. Scale rating of knowledge equivalent are: 
1=poor, 2=below average, 3=average, 4=above average, 5=outstanding. 
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3. What is your knowledge of the rate, dosing, and set up of IV 
amiodarone infusion?
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Results of Baseline Nursing Staff Knowledge Assessment Related to Amiodarone Infusion 
(Before Educational Program) 
 
 
 
Figure H4. Breakdown results of nursing staff baseline knowledge assessment related to 
amiodarone infusion based on the designated question. Scale rating of knowledge equivalent are: 
1=poor, 2=below average, 3=average, 4=above average, 5=outstanding. 
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Results of Baseline Nursing Staff Knowledge Assessment Related to Amiodarone Infusion 
(Before Educational Program) 
 
 
Figure H5. Breakdown results of nursing staff baseline knowledge assessment related to 
amiodarone infusion based on the designated question. Scale rating of knowledge equivalent are: 
1=poor, 2=below average, 3=average, 4=above average, 5=outstanding. 
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Results of Baseline Nursing Staff Knowledge Assessment Related to Amiodarone Infusion 
(Before Educational Program) 
 
 
 
Figure H6. Breakdown results of nursing staff baseline knowledge assessment related to 
amiodarone infusion based on the designated question. Scale rating of knowledge equivalent are: 
1=poor, 2=below average, 3=average, 4=above average, 5=outstanding. 
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Results of Baseline Nursing Staff Knowledge Assessment Related to Amiodarone Infusion 
(Before Educational Program) 
 
 
 
 
Figure H7. Breakdown results of nursing staff baseline knowledge assessment related to 
amiodarone infusion based on the designated question. Scale rating of knowledge equivalent are: 
1=poor, 2=below average, 3=average, 4=above average, 5=outstanding. 
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Results of Baseline Nursing Staff Knowledge Assessment Related to Amiodarone Infusion 
(Before Educational Program) 
 
 
 
Figure H8. Breakdown result of nursing staff baseline assessment of their preferred intravenous 
(IV) gauge size, and site when infusing amiodarone. 
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Results of Nursing Staff Knowledge Reassessment Post- Educational Program Related to 
Amiodarone Infusion 
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Figure I1. Breakdown results of nursing staff knowledge reassessment related to 
amiodarone infusion based on the designated question. Scale rating of knowledge 
equivalent are: 1=poor, 2=below average, 3=average, 4=above average, 5=outstanding. 
AMIODARONE-INDUCED PHLEBITIS 43 
Appendix I 
 
Results of Nursing Staff Knowledge Reassessment Post- Educational Program Related to 
Amiodarone Infusion 
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2. How familiar are you with the possible side effects of 
peripheral amiodarone infusion?
1
2
3
4
5
Figure I2. Breakdown results of nursing staff knowledge reassessment related to 
amiodarone infusion based on the designated question above. Scale rating of knowledge 
equivalent are: 1=poor, 2=below average, 3=average, 4=above average, 5=outstanding. 
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Results of Nursing Staff Knowledge Reassessment Post- Educational Program Related to 
Amiodarone Infusion 
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Figure I3. Breakdown results of nursing staff knowledge reassessment related to 
amiodarone infusion based on the designated question above. Scale rating of knowledge 
equivalent are: 1=poor, 2=below average, 3=average, 4=above average, 5=outstanding. 
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Results of Nursing Staff Knowledge Reassessment Post- Educational Program Related to 
Amiodarone Infusion 
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Figure I4. Breakdown results of nursing staff knowledge reassessment related to 
amiodarone infusion based on the designated question above. Scale rating of knowledge 
equivalent are: 1=poor, 2=below average, 3=average, 4=above average, 5=outstanding. 
AMIODARONE-INDUCED PHLEBITIS 46 
Appendix I 
Results of Nursing Staff Knowledge Reassessment Post- Educational Program Related to 
Amiodarone Infusion 
 
 
 
 
 
 
  
0%2%
12%
48%
38%
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Figure I5. Breakdown results of nursing staff knowledge reassessment related to 
amiodarone infusion based on the designated question above. Scale rating of 
knowledge equivalent are: 1=poor, 2=below average, 3=average, 4=above average, 
5=outstanding. 
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Results of Nursing Staff Knowledge Reassessment Post- Educational Program Related to 
Amiodarone Infusion 
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Figure I6. Breakdown results of nursing staff knowledge reassessment related to 
amiodarone infusion based on the designated question above. Scale rating of knowledge 
equivalent are: 1=poor, 2=below average, 3=average, 4=above average, 5=outstanding. 
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Results of Nursing Staff Knowledge Reassessment Post- Educational Program Related to 
Amiodarone Infusion 
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phlebitis to appear?
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Figure I7. Breakdown results of nursing staff knowledge reassessment related to 
amiodarone infusion based on the designated question above. Scale rating of knowledge 
equivalent are: 1=poor, 2=below average, 3=average, 4=above average, 5=outstanding. 
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Results of Nursing Staff Knowledge Reassessment Post- Educational Program Related to 
Amiodarone Infusion 
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Figure I8. Breakdown result of nursing staff reassessment of their preferred intravenous (IV) 
gauge size, and site when infusing amiodarone. 
